IMMUNEONCO-B
- Country
- 🇭🇰Hong Kong, China
- Ownership
- -
- Established
- 2015-06-18
- Employees
- 150
- Market Cap
- -
- Website
- http://cn.immuneonco.com
- Introduction
Yiming Angke Biomedical Technology (Shanghai) Co., Ltd. is a scientific research-oriented biotechnology company dedicated to developing innovative cancer immunotherapy. The company was incorporated in 2015 and is one of the few biotechnology companies in the world that can systematically utilize innate immunity and adaptive immune systems. By strictly adhering to the “Drug-by-Design” concept and using our R&D platform, we have designed a rich pipeline portfolio, including more than ten innovative drug candidates and eight ongoing clinical projects. Our pipeline is based on the deep and broad asset portfolio of innate immunity, which reflects our deep understanding of cutting-edge tumor biology and immunology, as well as our expertise in turning scientific research into drug candidates.
A Study of IMC-001 on Improved Atherosclerotic Plaque Stability in Patients of ACS
- Conditions
- Atherosclerosis
- Interventions
- Drug: Optimal medical treatment
- First Posted Date
- 2025-01-23
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT06788431
A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors
- First Posted Date
- 2025-01-08
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT06764836
- Locations
- 🇨🇳
ZhongShan Hospital Fudan University, Shanghai, Shanghai, China
A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer
- Conditions
- TNBCNSCLC
- Interventions
- Drug: Chemotherapy (pemetrexed + cisplatin/carboplatin)Drug: Chemotherapy (paclitaxel + cisplatin/carboplatin)Drug: Chemotherapy(Nab-paclitaxel)
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 148
- Registration Number
- NCT06746870
IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)
- Conditions
- Chronic Myelomonocytic Leukemia
- Interventions
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 170
- Registration Number
- NCT06647862
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳China-Japan Friendship Hospita, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma
- Conditions
- Classic Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 202
- Registration Number
- NCT06465446
A Study Of IMM47 In Subjects With Advanced Solid Tumors
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05985083
- Locations
- 🇦🇺
Scientia Clinical Research Ltd, NSW, Sydney, New South Wales, Australia
🇦🇺Icon Cancer Centre South Brisbane, QLD, Brisbane, Queensland, Australia
🇦🇺John Flynn Private Hospital, Gold Coast, Queensland, Australia
IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT05972460
- Locations
- 🇨🇳
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT05860075
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences and Peking Union Medical College,, Tianjin, Tianjin, China
Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas
- Conditions
- Solid TumorClassic Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 309
- Registration Number
- NCT05833984
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, China
🇨🇳Shandong Provincial Institute of Cancer Prevention and Treatment, Jinan, China
🇨🇳The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, China
Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 154
- Registration Number
- NCT05805943
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China